monopar.jpg
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
09 sept. 2020 08h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing...
monopar.jpg
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
19 août 2020 08h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit,...
monopar.jpg
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
12 août 2020 08h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
monopar.jpg
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
10 août 2020 08h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI),...
monopar.jpg
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
06 août 2020 16h05 HE | Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...
monopar.jpg
Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
07 mai 2020 09h00 HE | Monopar Therapeutics Inc.
CHICAGO, May 07, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics...
monopar.jpg
Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
18 févr. 2020 09h00 HE | Monopar Therapeutics Inc.
CHICAGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR) today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate...
monopar.jpg
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
23 déc. 2019 12h30 HE | Monopar Therapeutics Inc.
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’...
monopar.jpg
Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
20 déc. 2019 16h46 HE | Monopar Therapeutics Inc.
CHICAGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full...
monopar.jpg
Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
18 déc. 2019 19h52 HE | Monopar Therapeutics Inc.
CHICAGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The...